MBS-303 - Drug Targets, Indications, Patents - Synapse - Patsnap

mbs303 MBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. The. MBS-303: CD20CD3Beijing Mabworks Biotech Co., Ltd. ()12

mbs303, MBS303MSC303 (MBS303 as the intravenous formulation, MSC303 as the subcutaneous formulation) is an innovative CD20CD3 T-cell engager. MBS303 has initiated clinical trials.